Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biotechnology firm DermTech has been issued a patent entitled 'method for detection of melanoma' which includes claims focused on non-invasive methods for detecting early-stage melanoma and for staging, and claims for monitoring melanoma in a subject.
Subscribe to our email newsletter
The patent claims the use of DermTech’s ‘tape stripping’ technology for the purposes of detecting, staging and monitoring melanoma. The methods claimed in the patent focus on the use of DermTech’s EGIR (epidermal genetic information retrieval, a skin sampling technique known as ‘tape strippin’ in combination with a molecular diagnostic assay). The patent also claims the use of evaluating additional biomarkers based upon differences in gene expression such that a change in these messenger RNAs is indicative of late-stage melanoma. The ability to detect, stage and monitor disease is critical for improved clinical outcomes.
George Schwartz, CEO, DermTech, said: “DermTech welcomes the issuance of this patent as it will allow us to move forward and more fully develop and position our core EGIR technology for the staging as well as the detection, of melanoma. This patent is an important addition to our intellectual property portfolio.”